Making circadian cancer therapy practical

Integrative Cancer Therapies

Volumn 8, Issue 4, 2009, Pages 371-386

  Block, Keith I ^a   Block, Penny B ^a   Fox, Susan Reynolds ^a   Birris, Jamie Stouffer ^b   Feng, April Y ^a   De La Torre, Michael ^a   Nathan, Deva ^a   Tothy, Peter ^a   Maki, Amanda K ^a   Gyllenhaal, Charlotte ^a  

^a Block Center for Integrative Cancer Treatment   (United States)

^b THE CHICAGO SCHOOL OF PROFESSIONAL PSYCHOLOGY   (United States)

Author keywords

Chronotherapy; Circadian; Diet; Exercise; Lifestyle; Meditation; Rest activity

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; INSULIN; IRINOTECAN; MELATONIN; OMEGA 3 FATTY ACID; OXALIPLATIN; SOMATOMEDIN;

ANEMIA; ANOREXIA; ASTRAGALUS MEMBRANACEUS; BLOOD CLOTTING DISORDER; CACHEXIA; CANCER SURVIVAL; CARBOHYDRATE INTAKE; CHRONOTHERAPY; CIRCADIAN RHYTHM; COGNITIVE THERAPY; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DIET; EXERCISE; FATIGUE; FEBRILE NEUTROPENIA; GANODERMA LUCIDUM; HUMAN; IMMUNITY; KAPLAN MEIER METHOD; LENTINULA EDODES; LIFESTYLE MODIFICATION; LIGHT EXPOSURE; MEDITATION; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; REST; REVIEW; RHODIOLA; SLEEP; SOCIAL SUPPORT; STRESS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

CHRONOTHERAPY; DIET THERAPY; EXERCISE; HUMANS; LIFE STYLE; MIND-BODY THERAPIES; NEOPLASMS;

EID: 77949413144     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735409352028     Document Type: Review

References (95)

1. Block KI. Life Over Cancer. New York, NY: Bantam; 2009.
2. Pati AK, Parganiha A, Kar A, Soni R, Roy S, Choudhary V. Alterations of the characteristics of the circadian restactivity rhythm of cancer in-patients. Chronobiol Int. 2007; 24:1179-1197.
3. Mormont MC, Waterhouse J, Bleuzen P, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000;6:3038-3045.
4. Innominato PF, Focan C, Gorlia T, et al. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 2009;69:4700-4707.
5. Germaine A, Buysse DJ, Kupfer DJ. Preliminary validation of a new device for studying sleep. Abstract presented at: "SLEEP 2006"-20th anniversary meeting of the Associated Professional Sleep Societies (APSS); June 17-22, 2006; Salt Lake City, UT.
6. Froy O. The relationship between nutrition and circadian rhythms in mammals. Front Neuroendocrinol. 2007;28:61-71.
7. Kohsaka A, Laposky AD, Ramsey KM, et al. High-fat dietdisrupts behavioral and molecular circadian rhythms in mice. Cell Metab. 2007;6:414-421.
8. Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A. 2009;106:4069-4070.
9. Boden G, Ruiz J, Urbain JL, Chen X. Evidence for a circadian rhythm of insulin secretion. Am J Physiol Endocrinol Metabol. 1996;276:E246-E52.
10. Morgan L, Hampton S, Gibbs M, Arendt J. Circadian aspects of postprandial metabolism. Chronobiol Int. 2003; 20:795-808.
11. Dos Santos ML, Aragon FF, Padovani CR, Pimenta WP. Daytime variations in glucose tolerance in people with impaired glucose tolerance. Diabetes Res Clin Pract. 2006; 74:257-262.
12. Kanabrocki EL, Hermida RC, Wright M, et al. Circadian variation of serum leptin in healthy and diabetic men. Chronobiol Int. 2001;18:273-283.
13. Nakamura Y, Sanematsu K, Ohta R, et al. Diurnal variation of human sweet taste recognition thresholds is correlated with plasma leptin levels. Diabetes. 2008;57:2661-2665.
14. Lowden A, Holmbäck U, Akerstedt T, Forslund J, Lennernäs M, Forslund A. Performance and sleepiness during a 24 h wake in constant conditions are affected by diet. Biol Psychol. 2004;65:251-263.
15. Takeda E, Terao J, Nakaya Y, et al. Stress control and human nutrition. J Med Invest. 2004;51:139-145.
16. Markus CR, Olivier B, de Haan EH. Whey protein rich in alphalactalbumin increases the ratio of plasma tryptophan to the sum of the other large neutral amino acids and improves cognitive performance in stress-vulnerable subjects. Am J Clin Nutr. 2002;75:1051-1056.
17. Fernstrom JD, Fernstrom MH. Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr. 2007;137(6 suppl 1):1539S-1547S.
18. Merritt SL, Gyllenhaal C, Peterson SD, Block KI, Gochenour T. Herbal remedies: efficacy in controlling sleepiness and promoting sleep. Nurse Pract Forum. 2000;11:87-100.
19. Gyllenhaal C, Merritt SL, Peterson SD, Block KI, Gochenour T. Efficacy and safety of herbal stimulants and sedatives in sleep disorders. Sleep Med Rev. 2000;4:229-251.
20. Block KI, Gyllenhaal C, Mead MN. Safety and efficacy of herbal sedatives in cancer care. Integr Cancer Ther. 2004; 3:128-148.
21. Barton DL, Soori GS, Bauer BA, et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA [published online ahead of print May 6, 2009]. Support Care Cancer. DOI 10.1007/s00520-009-0642-2.
22. Garzón C, Guerrero JM, Aramburu O, Guzmán T. Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: a randomized, double-blind, placebo-controlled study. Aging Clin Exp Res. 2009;21:38-42.
23. Dimeo F, Fetscher S, Lange W, Mertelsmann R, Keul J. Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. Blood. 1997;90:3390-3394.
24. Alessi CA, Martin JL, Webber AP, Cynthia Kim E, Harko JO, Josephson KR. Randomized, controlled trial of a nonpharmacological intervention to improve abnormal sleep-wake patterns in nursing home residents. J Am Geriatr Soc. 2005; 53:803-810.
25. Liu L, Marler MR, Parker BA, et al. The relationship between fatigue and light exposure during chemotherapy. Support Care Cancer. 2005;13:1010-1017.
26. Yoon IY, Jeong JU, Kwon KB, Kang SB, Song BF. Bright light exposure at night and light attenuation in the morning improve adaptation of night shift workers. Sleep. 2002;25:351-356.
27. Eastman CI, Boulos Z, Terman M, Campbell SS, Dijk, DJ, Lewy AJ. Light treatment for sleep disorders: consensus report. VI. Shift work. J Biol Rhythms. 1995;10:157-164.
28. Friedman L, Zeitzer JM, Kushida C, et al. Scheduled bright light for treatment of insomnia in older adults. J Am Geriatr Soc. 2009;57:441-452.
29. Campbell SS, Terman M, Lewy AJ, Dijk DJ, Eastman CI, Boulos Z. Light treatment for sleep disorders: consensus report. V. Age-related disturbance. J Biol Rhythms. 1995;10:151-154.
30. King AC, Oman RF, Brassington GS, Bliwise DL, Haskell WL. Moderate-intensity exercise and self-rated quality of sleep in older adults: a randomized controlled trial. JAMA. 1997; 277:32-37.
31. Eastman CI, Hoese EK, Youngstedt SD, Liu L. Phase-shifting human circadian rhythms with exercise during the night shift. Physiol Behav. 1995;58:1287-1291.
32. Baehr EK, Eastman CI, Revelle W, Olson SH, Wolfe LF, Zee PC. Circadian phase-shifting effects of nocturnal exercise in older compared with young adults. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1542-R1550.
33. Barger LK, Wright KP Jr, Hughes RJ, Czeisler CA. Daily exercise facilitates phase delays of circadian melatonin rhythm in very dim light. Am J Physiol Regul Integr Comp Physiol. 2004;286:R1077-R1084.
34. Massion AO, Teas J, Hebert JR, Wertheimer MD, Kabat-Zinn J. Meditation, melatonin and breast/prostate cancer: hypothesis and preliminary data. Med Hypotheses. 1995;44:39-46.
35. Harinath K, Malhotra AS, Pal K, et al. Effects of Hatha yoga and Omkar meditation on cardiorespiratory performance, psychologic profile, and melatonin secretion. J Altern Complement Med. 2004;10:261-268.
36. Solberg EE, Holen A, Ekeberg Ø, Østerud B, Halvorsen R, Sandvik L. The effects of long meditation on plasma melatonin and blood serotonin. Med Sci Monit. 2004;10:CR96-CR101.
37. Tooley GA, Armstrong SM, Norman TR, Sali A. Acute increases in night-time plasma melatonin levels following a period of meditation. Biol Psychol. 2000;53:69-78.
38. Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology. 2004;29:448-474.
39. Berger AM, Kuhn BR, Farr LA, et al. Behavioral therapy intervention trial to improve sleep quality and cancer-related fatigue. Psychooncology. 2009;18:634-646.
40. Dirksen SR, Epstein DR. Efficacy of an insomnia intervention on fatigue, mood and quality of life in breast cancer survivors. J Adv Nurs. 2008;61:664-675.
41. Chen HY, Chiang CK, Wang HH, et al. Cognitive-behavioral therapy for sleep disturbances in patients undergoing peritoneal dialysis: a pilot randomized controlled trial. Am J Kidney Dis. 2008;52:314-323.
42. Cohen L, Warneke C, Fouladi RT, Rodriguez MA, Chaoul- Reich A. Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma. Cancer. 2004;100: 2253-2260.
43. Du-Quiton J, Wood PA, Burch JB, et al. Actigraphic assessment of daily sleep-activity pattern abnormalities reflects selfassessed depression and anxiety in outpatients with advanced non-small cell lung cancer [published online ahead of print February 6, 2009]. Psychooncology. DOI 10.1002/pon.1539
44. Tarin D. New insights into the pathogenesis of breast cancer metastasis. Breast Dis. 2006-2007;26:13-25.
45. Wallace JM. Nutritional and botanical modulation of the inflammatory cascade-eicosanoids, cyclooxygenases, and lipoxygenases-as an adjunct in cancer therapy. Integr Cancer Ther. 2002;1:7-37.
46. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009; 27:3437-3444
47. Kelley DS, Rasooly R, Jacob RA, Kader AA, Mackey BE. Consumption of Bing sweet cherries lowers circulating concentrations of inflammation markers in healthy men and women. J Nutr. 2006;136:981-986.
48. Devaraj S, Leonard S, Traber MG, Jialal I. Gammatocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radic Biol Med. 2008;44:1203-1208.
49. Vgontzas AN, Chrousos GP. HPA axis and sleep. http://www.endotext.org/ adrenal/adrenal31/adrenalframe31.htm. Accessed August 10, 2009.
50. Myers JS. Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms. Oncol Nurs Forum. 2008;35:802-807.
51. Damsgaard CT, Lauritzen L, Calder PC, Kjaer TR, Frøkiaer H. Reduced ex vivo interleukin-6 production by dietary fish oil is not modified by linoleic acid intake in healthy men. J Nutr. 2009;139:1410-1414.
52. Rock CL, Natarajan L, Pu M, et al. Longitudinal biological exposure to carotenoids is associated with breast cancer-free survival in the Women's Healthy Eating and Living Study. Cancer Epidemiol Biomarkers Prev. 2009;18:486-494.
53. Kanabrocki EL, Murray D, Hermida RC, et al. Circadian variation in oxidative stress markers in healthy and type II diabetic men. Chronobiol Int. 2002;19:423-439.
54. Blanco RA, Ziegler TR, Carlson BA, et al. Diurnal variation in glutathione and cysteine redox states in human plasma. Am J Clin Nutr. 2007;86:1016-1023.
55. Blask DE. Melatonin, sleep disturbance and cancer risk. Sleep Med Rev. 2009;13:257-264.
56. Vujanovic NL, Basse P, Herberman RB, Whiteside TL. Antitumor functions of natural killer cells and control of metastases. Methods. 1996;9:394-408.
57. Block KI, Mead MN. Immune system effects of Echinacea, ginseng and astragalus: a review. Integr Cancer Ther. 2003; 2:247-267.
58. Zheng R, Jie S, Hanchuan D, Moucheng W. Characterization and immunomodulating activities of polysaccharide from Lentinus edodes. Int Immunopharmacol. 2005;5:811-820.
59. Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest. 2003;32:201-215.
60. Arjona A, Sarkar DK. The circadian gene mPer2 regulates the daily rhythm of IFN-gamma. J Interferon Cytokine Res. 2006;26:645-649.
61. Arjona A, Sarkar DK. Evidence supporting a circadian control of natural killer cell function. Brain Behav Immun. 2006; 20:469-476.
62. Bollinger T, Bollinger A, Skrum L, Dimitrov S, Lange T, Solbach W. Sleep-dependent activity of T cells and regulatory T cells. Clin Exp Immunol. 2008;155:231-238.
63. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20:42-51
64. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A. Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev. 2009;18:701-705.
65. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol. 2002;3:425-430.
66. Beer JH, Haeberli A, Vogt A, et al. Coagulation markers predict survival in cancer patients. Thromb Haemost. 2002;88:745-749.
67. von Tempelhoff GF, Schonmann N, Heilmann L, Pollow K, Hommel G. Prognostic role of plasmaviscosity in breast cancer. Clin Hemorheol Microcirc. 2002;26:55-61.
68. Guida M, Ravaioli A, Sileni VC, et al. Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (Italian Melanoma Intergroup) trial. J Transl Med. 2003;1:13.
69. Meehan KR, Zacharski LR, Moritz TE, Rickles FR. Pretreatment fibrinogen levels are associated with response to chemotherapy in patients with small cell carcinoma of the lung: Department of Veterans Affairs Cooperative Study 188. Am J Hematol. 1995;49:143-148.
70. Haus, E, Cusuols M, Sackett-Lundeen L, Swoyer J. Circadian variation in blood coagulation parameters, alpha-antitrypsin antigen and platelet aggregation and retention in clinically healthy subjects. Chronobiol Int. 1990;7:203-216.
71. Colantonio D, Casale R, Abruzzo BP, Lorenzetti G, Pasqualetti P. Circadian distribution in fatal pulmonary thromboembolism. Am J Cardiol. 1989;64:403-404.
72. Kapiotis S, Jilma B, Quehenberger P, Ruzicka K, Handler S, Speiser W. Morning hypercoagulability and hypofibrinolysis. Circulation. 1997;96:19-21.
73. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92:994-1000.
74. Ramos MI, Cardoso MJ, Vaz F, et al. Influence of the grade of anxiety and level of cortisol on post-surgical recovery [in Spanish]. Actas Esp Psiquiatr. 2008;36:133-137.
75. Lissoni P, Messina G, Balestra A, et al. Efficacy of cancer chemotherapy in relation to synchronization of cortisol rhythm, immune status and psychospiritual profile in metastatic nonsmall cell lung cancer. In Vivo. 2008;22:257-262.
76. Monograph. Eleutherococcussenticosus. Altern Med Rev. 2006; 11:151-155.
77. Bystritsky A, Kerwin L, Feusner JD. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Altern Complement Med. 2008;14:175-180.
78. Kimura K, Ozeki M, Juneja LR, Ohira H. L-Theanine reduces psychological and physiological stress responses. Biol Psychol. 2007;74:39-45.
79. Kim WK, Jung JW, Ahn NY, et al. Anxiolytic-like effects of extracts from Albizzia julibrissin bark in the elevated plusmaze in rats. Life Sci. 2004;75:2787-2795.
80. Hershman D, McBride R, Jacobson JS, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol. 2005;23:6639-6646.
81. Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006;24:2368-2375.
82. Lis CG, Grutsch JF, Wood P, You M, Rich I, Hrushesky WJ. Circadian timing in cancer treatment: the biological foundation for an integrative approach. Integr Cancer Ther. 2003; 2:105-111.
83. Halberg F, Cornélissen G, Ulmer W, et al. Cancer chronomics III: Chronomics for cancer, aging, melatonin and experimental therapeutics researchers. J Exp Ther Oncol. 2006;6:73-84.
84. Mormont MC, Levi F. Cancer chronotherapy: principles, applications and perspectives. Cancer. 2003;97:155-169.
85. Calabrese C, Myer S, Munson S, Turet P, Birdsall TC. A crossover study of the effect of a single oral feeding of medium chain triglyceride oil vs. canola oil on post-ingestion plasma triglyceride levels in healthy men. Altern Med Rev. 1999;4:23-28.
86. Heys SD, Walker LG, Deehan DJ, Eremin OE. Serum albumin: a prognostic indicator in patients with colorectal cancer. J R Coll Surg Edinb. 1998;43:163-168.
87. Argiles JM. Cancer-associated malnutrition. Eur J Oncol Nurs. 2005;9(suppl 2):S39-S50.
88. Oh EY, Wood PA, Du-Quiton J, Hrushesky WJ. Seasonal modulation of post-resection breast cancer metastasis. Breast Cancer Res Treat. 2008;111:219-228.
89. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.
90. Falcone A, Ricci S, Brunett I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670-1676.
91. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as firstline treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006;94:798-805.
92. Skof E, Rebersek M, Hlebanja Z, Ocvirk J. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer. 2009;9:120.
93. Santoro A, Comandone A, Rimassa L, et al. A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Ann Oncol. 2008;19:1888-1893.
94. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005;23:4866-4875.
95. Gluzman A, Rubinov K, Mermershtain W, Man S, Ariad S, Lavrenkov K. Retrospective comparison of two different schedules of irinotecan, 5-fluorouracil and folinic acid in previously untreated patients with advanced colorectal carcinoma: a single institution experience. J Chemother. 2007; 19:739-743.